Eton Pharmaceuticals (NASDAQ:ETON) Stock Keeps “Buy” Rating at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 32.23% from the company’s previous close.

Several other research firms have also commented on ETON. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group increased their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. B. Riley Financial reiterated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $67.50.

Eton Pharmaceuticals Price Performance

NASDAQ ETON traded down $0.39 during trading on Wednesday, hitting $52.94. 284,421 shares of the stock traded hands, compared to its average volume of 449,204. Eton Pharmaceuticals has a 12-month low of $14.27 and a 12-month high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The firm has a 50-day simple moving average of $56.13 and a 200-day simple moving average of $40.69. The company has a market capitalization of $1.51 billion, a P/E ratio of 139.39 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $37.59 million during the quarter, compared to analyst estimates of $27.11 million. As a group, analysts predict that Eton Pharmaceuticals will post 1.13 EPS for the current year.

Insider Buying and Selling at Eton Pharmaceuticals

In other news, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This trade represents a 40.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This trade represents a 45.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 79,166 shares of company stock valued at $4,809,672 in the last quarter. 16.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Toth Financial Advisory Corp bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at about $43,000. Persistent Asset Partners Ltd bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at about $90,000. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals during the 4th quarter valued at about $50,000. State of Wyoming bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at about $107,000. Finally, Quantbot Technologies LP bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at about $165,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.